Trisalus Life Sciences, INC 8-K filings

TriSalus Life Sciences successfully closed its exchange offer and consent solicitation, issuing 2,110,366 shares of common stock in exchange for tendered warrants.

TriSalus Life Sciences successfully concluded its warrant exchange offer, resulting in the amendment of terms for its public warrants but not for private placement or working capital warrants.

TriSalus Life Sciences is offering to exchange outstanding warrants for common stock and seeking consent to amend the warrant agreement to simplify its capital structure.

TriSalus Life Sciences announced a 116% increase in revenue for Q1 2024 compared to Q1 2023, along with securing up to $50 million in debt financing.

TriSalus Life Sciences has increased its board size to ten and appointed Liselotte Hyveled as a new Class I director.

TriSalus Life Sciences has secured a debt financing facility of up to $50 million with OrbiMed to support the growth of its TriNav Infusion System and other strategic initiatives.

TriSalus Life Sciences has dismissed KPMG as its independent auditor and appointed Grant Thornton, citing no disagreements on accounting principles but acknowledging material weaknesses in internal controls.

TriSalus Life Sciences announced a 77% increase in fourth-quarter revenue and a 49% increase in full-year revenue for 2023, alongside significant clinical and regulatory advancements.

TriSalus Life Sciences reports preliminary unaudited 2023 financial results, showing a 49% increase in revenue year-over-year, driven by the TriNav Infusion System.

TriSalus Life Sciences granted its Chief Financial Officer, Sean Murphy, an option to purchase 125,000 shares of common stock as a performance incentive.